NZ723402B2 - Compositions of selenoorganic compounds and methods of use thereof - Google Patents
Compositions of selenoorganic compounds and methods of use thereof Download PDFInfo
- Publication number
- NZ723402B2 NZ723402B2 NZ723402A NZ72340216A NZ723402B2 NZ 723402 B2 NZ723402 B2 NZ 723402B2 NZ 723402 A NZ723402 A NZ 723402A NZ 72340216 A NZ72340216 A NZ 72340216A NZ 723402 B2 NZ723402 B2 NZ 723402B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- subject
- different compounds
- medicament
- methylseleno
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 21
- 150000001875 compounds Chemical class 0.000 title claims abstract 11
- AHKPTFGAKUWJCR-XDTOVJCPSA-N CC([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC=2C(N)=NC=NC12)[SeH])O)O Chemical compound CC([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC=2C(N)=NC=NC12)[SeH])O)O AHKPTFGAKUWJCR-XDTOVJCPSA-N 0.000 claims abstract 5
- 230000004153 glucose metabolism Effects 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000009229 glucose formation Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940065287 selenium compound Drugs 0.000 abstract 1
- 150000003343 selenium compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Abstract
The present application relates to compositions comprising selenium compounds, such as 5’-Methylselenoadenosine, Se-Adenosyl-L-homocysteine, Gamma-glutamyl-methylseleno-cysteine, a compound of Formula (I), Formula (II), or Formula (III), and combinations thereof, and methods of using the same for modulating glucose metabolism in a subject.
Claims (7)
1. Use of a composition for the manufacture of a medicament for replacing insulin in a subject, the composition comprising at least three different compounds selected from the group consisting of 5'-Methylselenoadenosine, Se-Adenosyl-L-homocysteine, and Gamma- glutamyl-methylseleno-cysteine, wherein the medicament is formulated for administration of the composition to the subject; wherein the composition contains at least about 0.033% (w/v) of each of the at least three different compounds.
2. Use of a composition for the manufacture of medicament for enhancing insulin activity in a subject, the composition comprising at least three different compounds selected from the group consisting of 5'-Methylse lenoadenosine, Se-Adenosyl-L-homocysteine, and Gamma-glutamyl-methylseleno-cysteine, wherein the medicament is formulated for administration of the composition to the subject; wherein the composition contains at least about 0.033% (w/v) of each of the at least three different compounds.
3. Use of a composition for the manufacture of a medicament for inhibiting glucose production in a subject, composition comprising at least three different compounds selected from the group consisting of 5'-Methylselenoadenosine, Se-Adenosyl-L-homocysteine, and Gamma- glutamyl-methylseleno-cysteine, wherein the medicament is formulated for administration of the composition to the subject; wherein the composition contains at least about 0.033% (w/v) of each of the at least three different compounds.
4. Use of a composition for the manufacture of a medicament for modulating glucose metabolism in a subject, the composition comprising at least three different compounds selected from the group consisting of 5'-Methylse lenoadenosine, Se-Adenosyl-L- homocysteine, and Gamma-glutamyl-methylseleno-cysteine, wherein the medicament is formulated for administration of the composition to the subject; wherein the composition contains at least about 0.033% (w/v) of each of the at least three different compounds.
5. The use of any one of claims 1, 2, 3 or 4, wherein the composition comprises at least 0.1% (w/v) of 5'-Methylselenoadenosine.
6. The use of any one of claims 1, 2, 3 or 4, wherein the composition further comprises insulin.
7. A composition comprising from 0.033% (w/v) to 99.9% (w/v) of at least three different compounds selected from the group consisting of 5'-Methylselenoadenosine, Se-Adenosyl- L-homocysteine, and Gamma-glutamyl-methylselenocysteine; and further comprising a carrier.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/029542 WO2015137983A1 (en) | 2014-03-14 | 2014-03-14 | Compositions of selenoorganic compounds and methods of use thereof |
| US14/855,128 US9642874B2 (en) | 2014-03-14 | 2015-09-15 | Compositions of selenoorganic compounds and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ723402A NZ723402A (en) | 2024-11-29 |
| NZ723402B2 true NZ723402B2 (en) | 2025-03-04 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016202535B2 (en) | Fused heterocyclic compounds as sodium channel modulators | |
| AU2016213805A1 (en) | Nuclear transport modulators and uses thereof | |
| WO2008067119A3 (en) | Novel compounds | |
| MY168201A (en) | Agricultural And Horticultural Fungicidal Composition | |
| HK1215579A1 (en) | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof | |
| WO2009082152A3 (en) | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient | |
| BR112014003063A2 (en) | "Antibacterial cyclopenta [c] pyrrol substituted 3,4-dihydro-1h- [1,8] naphthyridinones, pharmaceutical composition comprising said compounds, processes for their preparation and use". | |
| BR112015008717A2 (en) | compound, pharmaceutical composition, method of treating type II diabetes, use of the compound of formula (i), medication for treating type II diabetes | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| HK1219222A1 (en) | Formulation comprising a hypolipidemic agent | |
| BR112014002958A2 (en) | "Antibacterial piperidinyl substituted 3,4-dihydro-1h- [1,8] naphthyridinones, pharmaceutical composition comprising said compounds, processes for their preparation and use". | |
| WO2016025933A3 (en) | Substituted polycyclic antibacterial compounds | |
| PH12018500378B1 (en) | Novel annelated phenoxyacetamides | |
| PH12018500377A1 (en) | Novel annelated benzamides | |
| PH12015502684A1 (en) | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof | |
| IL276194B2 (en) | Compounds or pharmaceutical compositions comprising them for use in the treatment of paininhibiting | |
| TW200626593A (en) | Novel compounds | |
| WO2015042414A8 (en) | Multicyclic compounds and methods of using same | |
| MX2015007116A (en) | New substituted 1,4-dithiine derivatives and their use as fungicides. | |
| NZ587490A (en) | Anti-Microbial Compounds containing compounds with a sugar substituent | |
| WO2013106756A3 (en) | Antimicrobial agents | |
| PH12021552032A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| NZ723402B2 (en) | Compositions of selenoorganic compounds and methods of use thereof | |
| SG11201903014PA (en) | Urea derivative | |
| TW200740440A (en) | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient |